Rodriguez-PerezAI, LabandeiraCM, PedrosaMA, et al.Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun, 2021; 122:102683; doi: 10.1016/j.jaut.2021.102683
2.
TsoiJYH, CaiJ, SituJ, et al.Autoantibodies against angiotensin-converting enzyme 2 (ACE2) after COVID-19 infection or vaccination. J Med Virol, 2023; 95(12):e29313; doi: 10.1002/jmv
3.
ArthurJM, ForrestJC, BoehmeKW, et al.Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One, 2021; 16(9):e0257016; doi: 10.1371/journal.pone
4.
WangEY, MaoT, KleinJ, et al.Diverse functional autoantibodies in patients with COVID-19. Nature, 2021; 595(7866):283–288; doi: 10.1038/s41586-021-03631-y
5.
MurphyWJ, LongoDL. A possible role for anti-idiotype antibodies in SARS-CoV-2 infection and vaccination. N Engl J Med, 2022; 386(4):394–396; doi: 10.1056/NEJMcibr2113694
6.
ShirbhateE, PandeyJ, PatelVK, et al.Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: A potential approach for therapeutic intervention. Pharmacol Rep, 2021; 73(6):1539–1550; doi: 10.007/s43440-021-00303-6
7.
JinY, YangH, JiW, et al.Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, 2020; 12(4):372; doi: 10.3390/v12040372
8.
ZhouF, YuT, DuR, et al.Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet, 2020; 395(10229):1054–1062; doi: 10.16/S0140-6736(20)30566-3
9.
SamavatiL, UhalBD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol, 2020; 10:317; doi: 10.3389/fcimb.2020.00317
10.
CamargoRL, BombassaroB, Monfort-PiresM, et al.Plasma angiotensin II is increased in critical coronavirus disease 2019. Front Cardiovasc Med, 2022; 9:847809; doi: 10.3389/fcvm.2022.847809
11.
SriramK, InselPA. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance. Br J Pharmacol, 2020; 177(21):4825–4844; doi: 10.1111/bph.15082
12.
XuP, SriramulaS, LazartiguesE. ACE2/ANG-(1–7)/Mas pathway in the brain: The axis of good. Am J Physiol Regul Integr Comp Physiol, 2011; 300(4):R804–R817; doi: 10.1152/ajpregu.00222.2010
13.
ZhuL, SheZG, ChengX, et al.Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab, 2020; 31(6):1068.e3–1077.e3; doi: 10.16/j.cmet.2020.04.021
14.
AbadirPM, JainA, PowellLJ, et al.Discovery and validation of agonistic angiotensin receptor autoantibodies as biomarkers of adverse outcomes. Circulation, 2017; 135(5):449–459; doi: 10.1161/CIRCULATIONAHA.116.022385
15.
TakahashiY, HagaS, IshizakaY, et al.Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther, 2010; 12(3):R85; doi: 10.1186/ar3012
16.
PedrosaMA, LabandeiraCM, ValenzuelaR, et al.AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability. Brain Behav Immun, 2023; 108:255–268; doi: 10.1016/j.bbi.2022.12.009
17.
KohlerH, PashovA, Kieber-EmmonsT. The promise of anti-idiotype revisited. Front Immunol, 2019; 10:808; doi: 10.3389/fimmu.2019.00808
